Maas Biolab is a small neuropharmaceutical company developing a treatment for amyotrophic lateral sclerosis – using cyclosporin as a neuro-protectant drug.

Maas Biolab’s patent and related intellectual property rights consist formulation patents and production patents for cyclosporins as neuroprotective agents.

More importantly, Maas Biolab has FDA Orphan Drug Designation for cyclosporin to treat ALS.

Cyclosporin Neuroprotection

Members of the cyclosporin family display powerful neuroprotective properties in neuro-degeneration by preventing or reducing neuron cell death, blocking critical enzymes and free radicals, and by protecting the mitochondria. Pre-clinical studies show cyclosporin-A to be a powerful neuroprotectant against ALS.

The robustness of cyclosporin neuroprotection in an animal model of ALS makes it likely that it will be the first drug to have significant effect in humans. Initially, Maas Biolab intends to undertake further research, drug development, and clinical trials moving cyclosporin toward regulatory approval for the treatment of ALS.

Our Management Team

President and CEO
Marcus F. Keep, M.D.

Dr. Marcus Keep is the founder and CEO of Maas Biolab.

 Dr. Keep is a board certified neurosurgeon in both the United States and Canada. He is a full time Trauma Neurosurgeon at Sanford Medical Center in Fargo, which is the only Level 1 (the highest level) Trauma Center for all of North Dakota. Dr. Keep is a member of the joint American Association and Congress of Neurological Surgeons-Section on NeuroTrauma & Critical Care since 2003.

His neurosurgery residency training was at the Montreal Neurological Institute, McGill University, Canada. Dr. Keep received his MD from the Medical University of South Carolina in Charleston. His bachelor of science in Chemistry was earned at University of South Carolina. Marcus’s bachelor of arts was in Religion from Dartmouth College, Hanover, New Hampshire.  


Director of Preclinical Development
Jenny Karlsson, Ph.D.


Jenny Karlsson, Ph.D., is a neuroscientist and Director of Preclinical Research at Maas Biolab. She was the Principal Investigator on Maas Biolab’s now completed intrathecal cyclosporin preclinical research funded by the National Institute of Neurological Disorders and Stroke (NINDS), a section of the National Institutes of Health (NIH). Dr Karlsson earned her Ph.D. at the Section for Neuronal Survival, Lund University, Sweden, studying transplantation of dopaminergic neurons in models of Parkinson’s Disease. She performed post-doctoral research studying ALS cyclosporin neuroprotection at the Pacific Biomedical Research Center, University of Hawaii together with Dr Keep. Dr. Karlsson has also held postdoctoral positions at Dept of Pathology (Neuropathology) and College of Pharmacy at University of Next Mexico followed by assistant research professor position at the University of New Mexico College of Pharmacy where she studied neurodegenerative effects of manganese and uranium inhalation exposure. She has been Director of Preclinical Research at Maas Biolab since 2006.

Director of Operations
Michael Vickers


Mr. Vickers is a graduate of the University of New Mexico’s Anderson Schools of Management where he received his Bachelors of Business Administration with a concentration in financial management. Vickers has previously overseen Maas Biolab’s SBIR grant project, Fort Detrick Tech Transfer Initiative project, and managed the company’s Defense Threat Reduction Agency contract.  Vickers serves as the primary contact for Maas Biolab’s day to day operations and coordinates its activities with contract research organizations and other collaborators.  In addition Mr. Vickers serves as the Chairman of the Nomination Committee for NeuroVive Pharmaceutical AB and is a Board member and Treasurer of the New Mexico Biotechnology and Biomedical Association NMBio.

Close Menu